Nora M. Navone

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

55h-index10.1kcitations493works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(285), Bone health and treatments(55), Cancer, Lipids, and Metabolism(50), Heme Oxygenase-1 and Carbon Monoxide(42), Cancer, Hypoxia, and Metabolism(41)

Publications493 total

KDM4A promotes NEPC progression through regulation of MYC expression
Cancer Letters·2025Open Access
Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer
Cell Reports·2025· 5 citedOpen Access
Abstract 2967: Bone voyage: FGFR1, stemness, and the Wnt trail to prostate cancer metastasis
Cancer Research·2025
Abstract 3123: Fracturing the tumor-bone alliance in metastatic prostate cancer with Ra-223
Cancer Research·2025
Supplementary figure 10 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 9 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 8 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 4 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 5 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 15 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 5 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 7 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary table 1 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 4 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 6 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 12 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 1 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 3 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 9 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
Supplementary figure 14 from Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
2024Open Access
page 1 of 25Next →

Frequent Co-authors

Christopher J. Logothetis(20), Patricia Troncoso(19), Eleni Efstathiou(10), Ana M. Aparicio(10), Elba S. Vázquez(9), Sankar N. Maity(8), Arul M. Chinnaiyan(7), Xinhai Wan(7), Xuhong Cao(6), Louis L. Pisters(5), Andrew C. von Eschenbach(5), Michael W. Starbuck(5), Paul G. Corn(5), John C. Araujo(4), Donna M. Peehl(4), Jun Yang(4), Matilde Olivé(4), Jun Yang(4), Vikas Kundra(4), Vassiliki Tzelepi(4)